Cell signaling and biological pathway in cardiovascular diseases

  • Cheong-Whan Chae
  • Yoo-Wook KwonEmail author


Currently, coronary artery disease accounts for a large proportion of deaths occurring worldwide. Damage to the heart muscle over a short period of time leads to myocardial infarction (MI). The biological mechanisms of atherosclerosis, one of the causes of MI, have been well studied. Resistin, a type of adipokine, is closely associated with intravascular level of low-density lipoprotein cholesterol and augmentation of the expression of adhesion molecules in endothelial cells. Therefore, resistin, which is highly associated with inflammation, can progress into coronary artery disease. Adenylyl cyclase associated protein 1, a binding partner of resistin, also plays an important role in inducing pro-inflammatory cytokines. The induction of these cytokines can aggravate atherosclerosis by promoting severe plaque rupture of the lesion site. Recently, drugs, such as statins that can inhibit inflammation have been extensively studied. The development of effective new drugs that can directly or indirectly block pro-inflammatory cytokines may have a great potential in the treatment of coronary artery disease in the future.


Myocardial infarction Atherosclerosis Inflammation Resistin Form cell 


Compliance with ethical standards

Conflict of interest

All authors declared no conflict of interest.


  1. Alpert JS (2018) The fourth edition of the universal definition of myocardial infarction. Am J Med 131:1265–1266CrossRefPubMedGoogle Scholar
  2. Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969CrossRefPubMedGoogle Scholar
  3. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, Ramires JA, Serrano CV Jr (2004) Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177:161–166CrossRefPubMedGoogle Scholar
  4. Aslanian AM, Charo IF (2006) Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 114:583–590CrossRefPubMedGoogle Scholar
  5. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11:997–1001CrossRefPubMedGoogle Scholar
  6. Balcer HI, Goodman AL, Rodal AA, Smith E, Kugler J, Heuser JE, Goode BL (2003) Coordinated regulation of actin filament turnover by a high-molecular-weight Srv2/CAP complex, cofilin, profilin, and Aip1. Curr Biol 13:2159–2169CrossRefPubMedGoogle Scholar
  7. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM (1990) Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260–1266CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bobryshev YV, Ivanova EA, Chistiakov DA, Nikiforov NG, Orekhov AN (2016) Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis. Biomed Res Int 2016:9582430CrossRefPubMedPubMedCentralGoogle Scholar
  9. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174:5789–5795CrossRefPubMedGoogle Scholar
  10. Brouwer IA, Wanders AJ, Katan MB (2013) Trans fatty acids and cardiovascular health: research completed? Eur J Clin Nutr 67:541–547CrossRefPubMedGoogle Scholar
  11. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R (2001) Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103:934–940CrossRefPubMedGoogle Scholar
  12. Calatayud S, Mitchell JA, Perretti M, Giuliano F, Warner TD (2002) Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. Eur J Pharmacol 440:71–77CrossRefPubMedGoogle Scholar
  13. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN (2017) Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl) 95:1153–1165CrossRefGoogle Scholar
  14. Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW, Lee J, Lee HJ, Lee TK, Park J, Hwang SJ, Kwon YW, Cho HJ, Oh BH, Park YB, Kim HS (2011) Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 57:99–109CrossRefPubMedGoogle Scholar
  15. Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS (2005) Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site. Diabetologia 48:1150–1158CrossRefPubMedGoogle Scholar
  16. Clearfield M (2006) Statins and the primary prevention of cardiovascular events. Curr Atheroscler Rep 8:390–396CrossRefPubMedGoogle Scholar
  17. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272CrossRefPubMedGoogle Scholar
  18. Dadu RT, Ballantyne CM (2014) Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 11:563–575CrossRefPubMedGoogle Scholar
  19. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG (2011) An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 9:74–86CrossRefPubMedGoogle Scholar
  20. Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L, Lampugnani MG, Dejana E (1996) Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 135:497–510CrossRefPubMedGoogle Scholar
  21. Devries-Seimon T, Li Y, Yao PM, Stone E, Wang Y, Davis RJ, Flavell R, Tabas I (2005) Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol 171:61–73CrossRefPubMedPubMedCentralGoogle Scholar
  22. Dolinkova M, Krizova J, Lacinova Z, Dolezalova R, Housova J, Krajickova J, Bosanska L, Papezova H, Haluzik M (2006) Polymorphisms of adiponectin and resistin genes in patients with obesity and anorexia nervosa. Cas Lek Cesk 145:562–566PubMedGoogle Scholar
  23. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, Majmudar MD, Lasitschka F, Etzrodt M, Waterman P, Waring MT, Chicoine AT, Van Der Laan AM, Niessen HW, Piek JJ, Rubin BB, Butany J, Stone JR, Katus HA, Murphy SA, Morrow DA, Sabatine MS, Vinegoni C, Moskowitz MA, Pittet MJ, Libby P, Lin CP, Swirski FK, Weissleder R, Nahrendorf M (2012) Myocardial infarction accelerates atherosclerosis. Nature 487:325–329CrossRefPubMedPubMedCentralGoogle Scholar
  24. Fasano T, Cefalu AB, Di Leo E, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, Guardamagna O, Averna M, Tarugi P (2007) A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 27:677–681CrossRefPubMedGoogle Scholar
  25. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383:60–68CrossRefPubMedGoogle Scholar
  26. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27:165–197CrossRefPubMedPubMedCentralGoogle Scholar
  27. Genser B, Marz W (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 95:393–404CrossRefPubMedGoogle Scholar
  28. Gerstmayer B, Kusters D, Gebel S, Muller T, Van Miert E, Hofmann K, Bosio A (2003) Identification of RELMgamma, a novel resistin-like molecule with a distinct expression pattern. Genomics 81:588–595CrossRefPubMedGoogle Scholar
  29. Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ (2003) The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305:27–34CrossRefPubMedGoogle Scholar
  30. Ginsberg H, Plutzky J, Sobel BE (1999) A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 6:337–346CrossRefPubMedGoogle Scholar
  31. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, Mcdonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, Investigators L-T (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380:2007–2017CrossRefPubMedPubMedCentralGoogle Scholar
  32. Greenow K, Pearce NJ, Ramji DP (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl) 83:329–342CrossRefGoogle Scholar
  33. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRefPubMedGoogle Scholar
  34. Hotamisligil GS (2010) Endoplasmic reticulum stress and atherosclerosis. Nat Med 16:396–399CrossRefPubMedPubMedCentralGoogle Scholar
  35. Hu WW, Tang CH, Sun Y, Lu TT, Jiang P, Wu YM, Wang CQ, Yang SF, Su CM (2017) Correlation between resistin gene polymorphism and clinical aspects of lung cancer. Medicine (Baltimore) 96:e9485CrossRefGoogle Scholar
  36. Jang JC, Li J, Gambini L, Batugedara HM, Sati S, Lazar MA, Fan L, Pellecchia M, Nair MG (2017) Human resistin protects against endotoxic shock by blocking LPS-TLR4 interaction. Proc Natl Acad Sci USA 114:E10399–E10408CrossRefPubMedGoogle Scholar
  37. Jiang S, Park DW, Tadie JM, Gregoire M, Deshane J, Pittet JF, Abraham E, Zmijewski JW (2014) Human resistin promotes neutrophil proinflammatory activation and neutrophil extracellular trap formation and increases severity of acute lung injury. J Immunol 192:4795–4803CrossRefPubMedPubMedCentralGoogle Scholar
  38. Kain V, Prabhu SD, Halade GV (2014) Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109:444CrossRefPubMedGoogle Scholar
  39. Kakurina GV, Kolegova ES, Kondakova IV (2018) Adenylyl Cyclase-Associated Protein 1: structure, Regulation, and Participation in Cellular Processes. Biochemistry (Mosc) 83:45–53CrossRefGoogle Scholar
  40. Kim KH, Zhao L, Moon Y, Kang C, Sul HS (2004) Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc Natl Acad Sci USA 101:6780–6785CrossRefPubMedGoogle Scholar
  41. Kitahara M, Kanaki T, Toyoda K, Miyakoshi C, Tanaka S, Tamaki T, Saito Y (1998) NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Jpn J Pharmacol 77:117–128CrossRefPubMedGoogle Scholar
  42. Kotila T, Kogan K, Enkavi G, Guo S, Vattulainen I, Goode BL, Lappalainen P (2018) Structural basis of actin monomer re-charging by cyclase-associated protein. Nat Commun 9:1892CrossRefPubMedPubMedCentralGoogle Scholar
  43. Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25:387–393CrossRefPubMedPubMedCentralGoogle Scholar
  44. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, Lee S, Kim JY, Lee J, Yang HM, Mook-Jung I, Nam KY, Chung J, Lazar MA, Kim HS (2014) Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 19:484–497CrossRefPubMedPubMedCentralGoogle Scholar
  45. Li AC, Glass CK (2002) The macrophage foam cell as a target for therapeutic intervention. Nat Med 8:1235–1242CrossRefPubMedGoogle Scholar
  46. Li N, Salter RC, Ramji DP (2011) Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem 112:675–683CrossRefPubMedGoogle Scholar
  47. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874CrossRefPubMedGoogle Scholar
  48. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143CrossRefPubMedGoogle Scholar
  49. Lusis AJ (2000) Atherosclerosis. Nature 407:233–241PubMedGoogle Scholar
  50. Macmicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323–350CrossRefPubMedGoogle Scholar
  51. Makkonen M, Bertling E, Chebotareva NA, Baum J, Lappalainen P (2013) Mammalian and malaria parasite cyclase-associated proteins catalyze nucleotide exchange on G-actin through a conserved mechanism. J Biol Chem 288:984–994CrossRefPubMedGoogle Scholar
  52. Mattila PK, Quintero-Monzon O, Kugler J, Moseley JB, Almo SC, Lappalainen P, Goode BL (2004) A high-affinity interaction with ADP-actin monomers underlies the mechanism and in vivo function of Srv2/cyclase-associated protein. Mol Biol Cell 15:5158–5171CrossRefPubMedPubMedCentralGoogle Scholar
  53. Mccafferty DM, Mudgett JS, Swain MG, Kubes P (1997) Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 112:1022–1027CrossRefPubMedGoogle Scholar
  54. Mclaren JE, Ramji DP (2009) Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 20:125–135CrossRefPubMedGoogle Scholar
  55. Mclaren JE, Michael DR, Ashlin TG, Ramji DP (2011) Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50:331–347CrossRefPubMedGoogle Scholar
  56. Moriya J (2018) Critical roles of inflammation in atherosclerosis. J Cardiol 20:18. Google Scholar
  57. Moriyama K, Yahara I (2002) Human CAP1 is a key factor in the recycling of cofilin and actin for rapid actin turnover. J Cell Sci 115:1591–1601PubMedGoogle Scholar
  58. Moss JW, Ramji DP (2016) Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 13:513–532CrossRefPubMedPubMedCentralGoogle Scholar
  59. Muller WA (2002) Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 82:521–533CrossRefPubMedGoogle Scholar
  60. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V (2008) Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 82:708–717CrossRefPubMedGoogle Scholar
  61. Nahrendorf M (2018) Myeloid cell contributions to cardiovascular health and disease. Nat Med 24:711–720CrossRefPubMedGoogle Scholar
  62. Naoumova RP, Patel DD, O’neill FH, Thompson GR, Knight BL (2003) Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest 33:88–91CrossRefPubMedGoogle Scholar
  63. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, Kameda-Takemura K (1995) Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96:1859–1865CrossRefPubMedPubMedCentralGoogle Scholar
  64. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, Cella M, Bernal-Mizrachi C (2012) Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem 287:11629–11641CrossRefPubMedPubMedCentralGoogle Scholar
  65. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Labuzek K, Herman ZS (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327–335CrossRefPubMedGoogle Scholar
  66. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Herman ZS (2005) Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46:377–386CrossRefPubMedGoogle Scholar
  67. Olivares-Silva F, Landaeta R, Aranguiz P, Bolivar S, Humeres C, Anfossi R, Vivar R, Boza P, Munoz C, Pardo-Jimenez V, Peiro C, Sanchez-Ferrer CF, Diaz-Araya G (2018) Heparan sulfate potentiates leukocyte adhesion on cardiac fibroblast by enhancing Vcam-1 and Icam-1 expression. Biochim Biophys Acta Mol Basis Dis 1864:831–842CrossRefPubMedGoogle Scholar
  68. Ono S (2013) The role of cyclase-associated protein in regulating actin filament dynamics—more than a monomer-sequestration factor. J Cell Sci 126:3249–3258CrossRefPubMedPubMedCentralGoogle Scholar
  69. Paiva L, Providencia R, Barra S, Dinis P, Faustino AC, Goncalves L (2015) Universal definition of myocardial infarction: clinical insights. Cardiology 131:13–21CrossRefPubMedGoogle Scholar
  70. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L (2004) Disulfide-dependent multimeric assembly of resistin family hormones. Science 304:1154–1158CrossRefPubMedGoogle Scholar
  71. Pine GM, Batugedara HM, Nair MG (2018) Here, there and everywhere: resistin-like molecules in infection, inflammation, and metabolic disorders. Cytokine 110:442–451CrossRefPubMedGoogle Scholar
  72. Porreca E, Di Febbo C, Baccante G, Di Nisio M, Cuccurullo F (2002) Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol 39:1752–1757CrossRefPubMedGoogle Scholar
  73. Sanchez-Solana B, Laborda J, Baladron V (2012) Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 26:110–127CrossRefPubMedGoogle Scholar
  74. Schutt CE, Myslik JC, Rozycki MD, Goonesekere NC, Lindberg U (1993) The structure of crystalline profilin-beta-actin. Nature 365:810–816CrossRefPubMedGoogle Scholar
  75. Segrest JP, Jones MK, De Loof H, Dashti N (2001) Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42:1346–1367PubMedGoogle Scholar
  76. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK (2015) KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 21:628–637CrossRefPubMedPubMedCentralGoogle Scholar
  77. Shao BZ, Han BZ, Zeng YX, Su DF, Liu C (2016) The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin 37:150–156CrossRefPubMedPubMedCentralGoogle Scholar
  78. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T (2002) Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51:1737–1744CrossRefPubMedGoogle Scholar
  79. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380:29–36CrossRefPubMedGoogle Scholar
  80. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001a) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMedGoogle Scholar
  81. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA (2001b) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98:502–506CrossRefPubMedGoogle Scholar
  82. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N (2008) HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 7:365–375CrossRefPubMedGoogle Scholar
  83. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI (2010) Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 14:1419–1431CrossRefPubMedGoogle Scholar
  84. Tekin A, Sezgin N, Katircibasi MT, Tekin G, Colkesen Y, Sezgin AT, Muderrisoglu H (2008) Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure. Coron Artery Dis 19:513–519CrossRefPubMedGoogle Scholar
  85. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Executive Group on Behalf of the Joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force for the Universal Definition of Myocardial, I (2018) Fourth universal definition of myocardial infarction. J Am Coll Cardiol 72:2231–2264CrossRefPubMedGoogle Scholar
  86. Tripathi P, Tripathi P, Kashyap L, Singh V (2007) The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol 51:443–452CrossRefPubMedGoogle Scholar
  87. Tsukano H, Gotoh T, Endo M, Miyata K, Tazume H, Kadomatsu T, Yano M, Iwawaki T, Kohno K, Araki K, Mizuta H, Oike Y (2010) The endoplasmic reticulum stress-C/EBP homologous protein pathway-mediated apoptosis in macrophages contributes to the instability of atherosclerotic plaques. Arterioscler Thromb Vasc Biol 30:1925–1932CrossRefPubMedGoogle Scholar
  88. Tuomisto TT, Lumivuori H, Kansanen E, Hakkinen SK, Turunen MP, Van Thienen JV, Horrevoets AJ, Levonen AL, Yla-Herttuala S (2008) Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res 78:175–184CrossRefPubMedGoogle Scholar
  89. Van De Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Guidelines ESCCFP (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945CrossRefPubMedGoogle Scholar
  90. Wang H, Chu WS, Hemphill C, Elbein SC (2002) Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 87:2520–2524CrossRefPubMedGoogle Scholar
  91. Yamagami H, Sakaguchi M, Furukado S, Hoshi T, Abe Y, Hougaku H, Hori M, Kitagawa K (2008) Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol 34:1353–1359CrossRefPubMedGoogle Scholar
  92. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK (2013) Foam cells in atherosclerosis. Clin Chim Acta 424:245–252CrossRefPubMedGoogle Scholar
  93. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH (2008a) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 105:13045–13050CrossRefPubMedGoogle Scholar
  94. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S (2008b) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 180:6988–6996CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2019

Authors and Affiliations

  1. 1.National Research Laboratory for Stem Cell Niche, Center for Medical InnovationSeoul National University HospitalSeoulRepublic of Korea
  2. 2.Biomedical Research InstituteSeoul National University HospitalSeoulRepublic of Korea
  3. 3.Department of MedicineSeoul National University College of MedicineSeoulRepublic of Korea

Personalised recommendations